Загрузка...
Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma
Anticancer agents that target both tumor cells and angiogenesis are of potential interest for glioblastoma (GB) therapy. One such agent is sorafenib (SFN), a tyrosine kinase inhibitor. However, poor aqueous solubility and undesirable side effects limit its clinical application, including local treat...
Сохранить в:
| Опубликовано в: : | Drug Deliv |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Taylor & Francis
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6225440/ https://ncbi.nlm.nih.gov/pubmed/30338715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10717544.2018.1507061 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|